teladoc tirzepatide Semaglutide & Weight Loss Medications Readout Newsletter: Makary hearing, Hims,

Smooth over face and neck, avoiding eye area

Tirzepatide has consistently shown greater weight loss than semaglutide at comparable doses in clinical trials, with some participants losing approximately 16% or more of their starting body weight. Choosing between the two compounds is a clinical decision based on individual health history, metabolic profile, and treatment goals, not simply which drug produces the largest number on paper

KPV is the C-terminal tripeptide lysine-proline-valine, a low-molecular-weight sequence frequently used in comparative small-peptide analytical work

Patients with obesity were classified into two cohorts: an AOM cohort that received tirzepatide (Zepbound) or semaglutide (Wegovy) during the identification period (index date = first AOM claim) and a non-AOM cohort with no evidence of AOM use during the study period